Related references
Note: Only part of the references are listed.Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors
Roberta Frapolli et al.
CLINICAL CANCER RESEARCH (2010)
Trabectedin therapy for sarcomas
Paolo G. Casali et al.
CURRENT OPINION IN ONCOLOGY (2010)
A Review of Trabectedin (ET-743): A Unique Mechanism of Action
Maurizio D'Incalci et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
J. M. Del Campo et al.
ANNALS OF ONCOLOGY (2009)
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
F. Grosso et al.
ANNALS OF ONCOLOGY (2009)
Trabectedin: an anticancer drug from the sea
Kristen N. Ganjoo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Claudia Forni et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
Patrick Schöffski et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: Which treatment to choose?
Peter Hohenberger et al.
ONCOLOGIST (2008)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Trabectedin- A review of its use in the management of soft tissue sarcoma and ovarian cancer
Natalie J. Carter et al.
DRUGS (2007)
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
L. Zelek et al.
BRITISH JOURNAL OF CANCER (2006)
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
